Cancer progression is associated with the development of antitumor autoantibodies in patients' sera. Although passive treatment with antitumor antibodies has exhibited remarkable therapeutic efficacy, inhibitory effects on tumor progression by endogenous antitumor autoantibodies (EAAs) have been limited. In this study, we show that P 4 N, a derivative of the plant lignan nordihydroguaiaretic acid (NDGA), enhanced the production of EAAs and inhibited tumor growth at low noncytotoxic concentrations via its immunoregulatory activity. Intratumoral injection of P 4 N improved the quantity and quality of EAAs, and passive transfer of P 4 N-induced EAAs dramatically suppressed lung metastasis formation and prolonged the survival of mice inoculated with metastatic CT26 tumor cells. P 4 N-induced EAAs specifically recognized two surface antigens, 78-kDa glucose-regulated protein (GRP78) and F1F0 ATP synthase, on the plasma membrane of cancer cells. Additionally, P 4 N treatment led to B-cell proliferation, differentiation to plasma cells, and high titers of autoantibody production. By serial induction of autocrine and paracrine signals in monocytes, P 4 N increased B-cell proliferation and antibody production via the leukotriene A4 hydrolase (LTA4H)/activin A/B-cell activating factor (BAFF) pathway. This mechanism provides a useful platform for studying and seeking a novel immunomodulator that can be applied in targeting therapy by improving the quantity and quality of the EAAs.
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endogenous antitumor autoantibody | P 4 N | B-cell proliferation | colorectal cancer | cancer immunotherapy C olorectal cancer (CRC) is the second most prevalent cancer in the western world and is also rapidly increasing in Asia (1) . It is well known that multiple genetic events involved in the development of this disease lead to the generation of tumor-associated antigens (TAAs) against which patients with CRC develop autoantibodies (2) . More than 100 TAAs have been identified by these endogenous antitumor autoantibodies (EAAs), including 78-kDa glucose-regulated protein [GRP78, also known as binding Ig protein (BiP)], p53, carcinoembryonic acid (CEA), and mucin 1 (MUC1) (2) . The use of these autoantibody signatures as biomarkers in the early detection of CRC has been proposed (3) (4) (5) . Typically, EAAs have not had a significant effect on tumor elimination, most likely due to immune tolerance induction by the tumor (6, 7) . However, extraction of EAAs from the sera of patients with cancer to activate the humoral immune response against some malignant tumors has been considered. A few EAAs selected from patients, such as SC-1 (anti-CD55), PAM-1 [anti-cysteine-rich fibroblast growth factor (anti-CFR1)], and PAT-SM6 (anti-GRP78), act directly against tumors and effectively kill them via antibody-mediated cellular cytotoxicity (8) . In addition, a natural human IgM autoantibody (PAT-SM6) selected from patients' sera against the cell surface GRP78 protein provides therapeutic effects for patients with cancer (9, 10) . Although the therapeutic effects of EAAs are ill-defined, these studies display their potential for clinical therapy.
Alternatively, passive immune therapeutics composed of antibodies ligated to targeted molecules (11) and directed against tumor growth factors (12) have been used clinically to induce apoptosis of tumor cells directly. Moreover, these passive therapeutic antibodies trigger complement-dependent cytotoxicity (CDC) or antibodydependent cellular cytotoxicity (ADCC) (12, 13) , promote phagocytosis by dendritic cells (DCs) (14) , induce cross-talk between immune cells [natural killer (NK) cells and DCs], produce immunomodulatory cytokines (type I and type II interferons) (12) , and enhance the cross-presentation of antigen-presenting cells (APCs) for the priming of CD8 + cytotoxic T lymphocytes (CTLs) (12, 14) . By these reactions, passive therapeutic antibodies can be effective agents for tumor inhibition. The effectiveness of therapeutic antitumor antibodies portends the potential of enhanced or improved EAAs to function as effective therapeutic entities.
Significance
This study finds that a small-molecule drug (P 4 N) is able to inhibit tumor growth by augmentation of endogenous antitumor autoantibodies (EAAs). We show that the enhancement of EAA activity by P 4 N is mediated through activation of the leukotriene A4 hydrolase (LTA4H)/activin A/B-cell activating factor (BAFF) pathway, revealing a valuable method for developing new immune modulators of tumor growth via humoral immunity. Typically, the effects of the humoral response on tumor inhibition are modest; however, the results of this study demonstrate that by removing the impediment to cancer cell destruction posed by low-activity autoantibodies, the realization of new, more potent immunotherapies for cancer treatment may be possible.
Recently, low-dose chemotherapy (metronomic chemotherapy) has been shown to induce an antitumor immune response and enhance the efficacy of cancer therapy. For example, the antimicrotubule taxanes (paclitaxel and docetaxel) were found to trigger the production of cytokines by macrophages to activate other immune cells, such as DCs (15) , NK cells (16) , and CTLs, against tumors (16, 17) . Paclitaxel also reduced the number of regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs), and led to the augmentation of the functions of CD4 and CD8 T cells (16, 17) . In other cases, DNA alkylating agents, such as cyclophosphamide and mafosfamide, in low doses selectively depleted Treg cells (18, 19) , caused an increase in effector T cells (Teff)/Treg cell ratios via up-regulation of the T helper (Th) 17 pathway (20) , and improved the outcome of tumor vaccinations against cancer (21) (22) (23) . Furthermore, doxorubicin, mitomycin C, vinblastine, and methotrexate in low doses have been found to up-regulate DC maturation, antigen processing, and antigen presentation, which led to synergistic antitumor effects of low-dose chemotherapy combined with a DC vaccine (24) (25) (26) . These various antitumor drugs in low doses can induce cell-mediated immunity against tumors, but they have less of a contribution to humoral immunity. Therefore, they have not been used to raise EAAs against tumor growth in patients. P 4 N, a derivative of nordihydroguaiaretic acid (NDGA), a natural product from the creosote bush, Larrea tridentate, is composed of two phenolic rings connected by long and flexible -CH 2 -CH 2 -linkers to piperidines (27) . Like methylated derivatives of NDGA, P 4 N has shown noteworthy antivirus and anticancer effects via competition with the transcription factor Sp1 for its DNA-binding site (27, 28) . P 4 N's parent compound, NDGA, is a potent antioxidant and has been shown to have promising applications in the treatment of multiple diseases, including cardiovascular disease and neurological disorders (29) . It also inhibits the growth of various tumors (30) , although it is substantially less potent than P 4 N (SI Appendix, Fig. S1 ) and likely has a different mechanism of action (28) . NDGA has immunoregulatory activities as well. It inhibits 5-lipoxygenase, suppresses the production of leukotriene B4 (LTB4), and activates macrophages (29) . The effect of P 4 N on immune function is unknown.
In this study, the immunoregulatory activity of low-dose P 4 N was investigated. Unlike previously described antitumor drugs, low-dose P 4 N contributes to humoral immunity by raising the titers and activities of autoantibodies against GRP78 and F1F0 ATP synthase on the surface of CT26 cells and inducing B-cell proliferation and differentiation of plasma cells. We show that low-dose P 4 N induces B-cell proliferation by activating leukotriene A4 hydrolase (LTA4H), thereby enhancing the production of LTB4 and stimulating monocytes to release proinflammatory cytokines. The release of activin A acts as an autocrine signal, stimulating B-cell activating factor (BAFF) production via activation of the ALK4/Smad3 pathway. BAFF then enhances B-cell proliferation and activation. To examine whether low-dose P 4 N causes immunoregulatory activity for the suppression of tumor growth, the effects of a single intratumoral injection with 2.5 mg/kg or 5 mg/kg of P 4 N into CT26 tumors in BALB/c or nude mice were monitored. Both doses of P 4 N significantly inhibited the growth of CT26 tumors in BALB/c mice, but had no effect on the growth of CT26 tumors in the immunodeficient nude mice (Fig. 1A) . As shown in Fig. 1B, CD8 + T-cell depletion attenuated the effect of P 4 Ninduced tumor inhibition. In contrast, B-cell depletion abolished the effect of P 4 N-induced tumor inhibition (Fig. 1B) . The tumorsuppressive effects of P 4 N were not the result of direct cytotoxicity of the drug, because there was no significant difference in tumor growth between P 4 N and PBS treatments in the B-celldepleted mice. These results suggested that a humoral immune response may play a major role in P 4 N-induced tumor inhibition.
Using an immunohistochemistry (IHC) assay, it was shown that P 4 N treatments led to the infiltration of immune cells, such as macrophages, DCs, and T or B cells, into the tumor area (Fig. 1C) . There was no significant difference between the two mouse strains in terms of the levels of macrophages and DCs in the tumors, but the levels of T and B cells in the tumors were higher in BALB/c mice than in nude mice (SI Appendix, Fig. S2 ). In addition, it was found that P 4 N treatments enhanced the expression levels of TNF-α and IL-8 in both strains of mice (Fig. 1D) . Taken together, these results indicate that low-dose P 4 N elicits certain immune responses in tumors, but only suppresses tumor growth in BALB/c mice, where adaptive immunity may play an important role.
To determine whether humoral immunity is involved in the antitumor activity of low-dose P 4 N, sera isolated from P 4 N-or vehicle (PBS)-treated CT26 tumor-bearing mice were passively transferred into BALB/c mice inoculated with metastatic CT26 cells. Within 18 d after tumor cell injection, untreated mice developed lung metastases, with metastatic nodules surrounding the lungs. Administration with antisera derived from PBS-treated mice decreased the number of metastatic nodules and the total weight of the lungs (Fig.  2 A and B) . P 4 N-derived antisera displayed an even stronger effect, dramatically inhibiting tumor colonization, as evidenced by the nearly complete lack of metastatic nodules and total lung weights approaching the total lung weights of normal mice. All mice treated with P 4 N antisera survived more than 60 d, a survival time threefold the survival time of the control groups (Fig. 2C) . These results suggested that the inhibition of tumor colonization by P 4 N antisera might be the result of P 4 N-induced EAAs in the sera.
The Effect of P 4 N on Production and Activity of Antitumor Autoantibodies. To eliminate the influence of T cells, the antisera were injected into CT26 tumor-containing immunodeficient mice. P 4 N antisera still significantly suppressed tumor growth in these mice, whereas PBS antisera had no significant effect on tumor growth (Fig. 3A) . Characterization of the antisera revealed that the titers of specific anti-CT26 antibodies in P 4 N antisera were higher than in PBS antisera, regardless of the time of harvest (Fig. 3B) , and the major classes of increased antibodies in P 4 N antisera were IgG1 and IgA (Fig. 3C ). Like normal mouse sera, PBS antisera only somewhat recognized the tumor cells in CT26 tumor tissue; however, the P 4 N antisera displayed a strong binding affinity for the cells (Fig. 3D) . Of interest are the antigens that are recognized by EAAs in sera derived from tumor-bearing mice. Fig. 3E shows that although both antisera recognized surface antigens on CT26 cells, P 4 N antisera was more proficient than PBS antisera. By confocal microscopy, the autoantibody-bound antigens on the plasma membrane were distributed in a speckled pattern, implying their presence in complexes associated with other cell surface proteins (Fig. 3F) . A Western blot assay determined that the autoantibodies in the antisera recognized 78-kDa and 55-kDa proteins on the membranes of CT26 cells (Fig. 3G) . The antigen profile on the cell membrane was further delineated by co-immunoprecipitation of a membrane protein extract with the antisera. Proteins of 78 kDa and 55 kDa were precipitated, along with at least six other proteins. The 78-kDa and 55-kDa proteins were identified by ultra performance liquid chromatography (UPLC) high-resolution tandem mass spectrometry (HRMS/MS) as GRP78 and F1F0 ATP synthase, respectively (SI Appendix, Fig. S3A ).
To determine if the antitumor effects of P 4 N antisera are mediated by antibodies directed at these two antigens, GRP78-and ATP synthase-specific peptides (SI Appendix, Fig. S3B ) were tested for their ability to neutralize the cytotoxic activities of the P 4 N-induced antitumor autoantibodies. First, it was established that P 4 N antisera is cytotoxic to CT26 cells in culture ( Fig. 3H ) and that the peptides were able to bind to the P 4 N antisera (SI Appendix, Fig. S3C ). Subsequently, the cytotoxic effects of P 4 N antisera combined with GRP78-and ATP synthase-specific peptides were analyzed. The results (Fig. 3I) showed that the peptides decreased the cytotoxicity of P 4 N antisera, confirming that P 4 N treatments enhance the production and activity of anti-GRP78 and anti-F1F0 ATP synthase autoantibodies that promote CT26 tumor inhibition.
The Effect of Low-Dose P 4 N on B-Cell Proliferation and Ig Regulation.
The immune modulation effects of P 4 N were investigated by testing the ability of low-dose P 4 N to affect the proliferation of human peripheral blood mononuclear cells (PBMCs) in vitro. As shown in SI Appendix, Fig. S4A , PBMC proliferation, as measured by the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide) colorimetric assay, was increased by 10-40%, depending on the dose of P 4 N. Flow cytometry analysis of B cells from six healthy individuals showed that P 4 N significantly increased the proliferation of the B-cell population in human PBMCs (SI Appendix, Fig. S4B ). B-cell proliferation was also analyzed in mouse splenocytes, and a similar P 4 N-induced increased in total splenic B-cell proliferation was observed (SI Appendix, Fig.  S4C ). Upon further analysis, it was determined that the increase in total B-cell proliferation was the result of the proliferation of naive B cells. P 4 N had no effect on the number of activated B cells in the absence of antigen stimulation. These results suggest that P 4 N treatments have similar effects in mice and humans.
Enhanced green fluorescent protein (EGFP) was used as a model antigen to monitor specific antibody production and B-cell differentiation after antigen stimulation. BALB/c mice were immunized and boosted using i.p. injections with the EGFP antigen combined with one-time or three-times weekly P 4 N injections. P 4 N dramatically enhanced total specific anti-EGFP Ig production, especially when EGFP was combined with P 4 N injections three times a week (SI Appendix, Fig. S4D ). In addition, immunization plus P 4 N significantly increased IgG1, IgG2b, and IgA production (SI Appendix, Fig. S4E ). These results indicate that P 4 N promotes specific antibody production by up-regulating the Th2-mediated immune response. Analysis of B-cell types revealed that both memory and plasma cells were increased after EGFP immunization (SI Appendix, Fig. S4F ). EGFP immunization combined with P 4 N resulted in an even larger stimulation of B-cell differentiation to plasma cells, suggesting that P 4 N treatment could promote enhanced antibody production. Another cell type in the peripheral tissue that is able to stimulate B-cell proliferation is the DC. The effects of P 4 N on mouse bone marrow-derived (mBM) DCs were analyzed, and the results showed P 4 N did not induce cell proliferation of mBM-DCs or increase their expression of BAFF (SI Appendix, Fig. S8 A and B). LTA4A expression was increased in the monocyte/macrophage population, but not in mBM-DCs (SI Appendix, Fig. S8C ).
To determine the factors involved in P 4 N-induced B-cell proliferation, the gene expression pattern of monocytes treated with P 4 N was analyzed by cDNA microarray. The results of this analysis revealed 26 up-regulated genes of cytokine-cytokine interaction [Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway] and 10 up-regulated genes of growth factor activity [Gene Ontology (GO): 0008083] in THP-1 cells following P 4 N treatment (Fig. 4B) . Based on these results, the factor most Number of lung metastases in each group was counted and expressed as the mean ± SD (n = 5 per group). Mean lung weight (B) and mean survival rate (C) of mice in each group (n = 7 per group) were calculated and plotted. Data were collected from two independent experiments. Significant differences between the P 4 N antisera group and the PBS antisera group were determined and labeled with **P < 0.01 and ***P < 0.001.
capable of activating B cells without antigen stimulation, BAFF (TNFSF13B), was chosen for further study, along with activin A (INHBA), because it is associated with BAFF expression.
Effect of P 4 N-Induced Inflammatory Monocytes on Activin A and BAFF Expression. It has been reported that inflammatory monocytes markedly enhance the production of activin A, which can stimulate APCs to express BAFF (31) . In accordance with these reports, we observed that low-dose P 4 N induced human PBMCs to increase their gene expression and protein production of activin A and BAFF (Fig.  5A ) in a dose-dependent manner (Fig. 5B) . P 4 N up-regulated mRNA expression of activin A at 2 h, whereas BAFF expression was elevated at 8 h (Fig. 5C) . Similar results were obtained in mouse splenocytes (SI Appendix, Fig. S9 ). These results imply that activin A release from P 4 N-treated monocytes stimulates the expression of BAFF.
Involvement of the ALK4/Smad3 Pathway in Activin A-Induced BAFF Expression. The pathways involved in activin A-induced BAFF expression after treatment with P 4 N were delineated through the use of SB431542, (an ALK4 inhibitor), A83-01 (an ALK4 inhibitor), SIS3 (a Smad3 inhibitor), SB203580 (a p38 inhibitor), and PD98059 (an ERK inhibitor). Inhibitors SB431542, A83-01, and SIS3 significantly reduced BAFF gene and protein expression, whereas inhibitors SB203580 and PD98059 had fewer effects, suggesting that the ALK4/Smad3 pathway mediates the activin A-induced expression of BAFF (Fig. 5 D and E) . Furthermore, conditioned medium from THP-1 cells treated with P 4 N increased the proliferation of B cells, whereas conditioned medium from THP-1 cells treated with P 4 N and the inhibitors SB431542, A83-01, or SIS3 lost its activity (Fig. 5F ). These results indicate that P 4 N-induced B-cell proliferation is likely due (F) Subcellular location of antigens recognized by the antisera was monitored by confocal microscopy. Alexa Fluor 568-conjugated anti-mouse Ig antibodies were used to display the presence of antisera (red). Alexa Fluor 488-Con A and DAPI were used to indicate the cell membrane (green) and the cell nucleus (blue), respectively. (G) Normal sera, PBS antisera, or P 4 N anti-sera were used to probe Western blots of membrane proteins of extracted from CT26 cells. Two bands of 78 kDa and 55 kDa were visualized: E-cadherin proteins were used as a loading control. For all results, significant differences between the P 4 N antisera group and the PBS antisera group were calculated and labeled with *P < 0.05. (H) Proliferation of CT26 cells treated with 1, 2, 4, or 8 μL of sera was analyzed by MTT assay. To create de-anti-CT26 antibody sera, the anti-CT26 autoantibodies from P 4 N antisera were presubtracted by CT26 cell binding. The data are reported as the proliferation index. Significant differences between the P 4 N-treated groups and the untreated group were indicated by *P < 0.05 (n = 5). (I) Cytotoxicity of P 4 N antisera after neutralization with ATPA and GRP78 peptides. (Magnification: C and F, 400×.)
to the action of BAFF that is induced by activin A through the ALK4/Smad3 pathway, Furthermore direct inhibition of activin A or BAFF by specific antibodies abolished the P 4 N-induced proliferation of isolated B cells (Fig. 5 G and H) .
The effect of P 4 N treatment on M1/M2 macrophage polarization was assessed by evaluating the mRNA expression of CD80 (M1) and CD163 (M2) in human macrophages by RT-PCR. The results showed that P 4 N treatments increased the expression of both CD80 and CD163 (SI Appendix, Fig. S10A ). In P4N-treated CT26 tumors, the expression of F4/80 (total macrophages), CD68 (M1), and CD163 (M2), as determined by IHC staining, was also increased in a time-dependent manner (SI Appendix, Fig. S10B ). Next, we sought to determine the molecular targets of P 4 N that mediate the response observed in this study. Docking analysis using Swiss Target Prediction and iGEMDOCK software identified the enzyme LTA4H as a potential target of P 4 N. P 4 N docked at a noncatalytic site of LTA4H compared with the small-molecule active site inhibitor RB3021 (Fig. 6A) . P 4 N also increased the synthesis of the proinflammatory mediator LTB4, a step catalyzed by LTA4H (32) (Fig. 6B) . These results indicate that the NDGA-derivative P 4 N is an LTA4H activator and not an LTA4H inhibitor like its parent molecule NDGA (33, 34) , which docks at the active site (SI Appendix, Fig. S11 ). NDGA has been shown to inhibit growth and proliferation and to induce apoptosis in multiple types of cancer cells in tissue culture, including lung, prostate, gastric, neuroblastoma, and breast cancer, through its effects on a variety of molecular targets (30) . The effect of NDGA compared with P 4 N on in vivo CT26 tumor growth was examined in this study (SI Appendix, Fig. S1B ), along with HT-29 tumor growth (SI Appendix, Fig. S1A ). Results showed that after 48 h of treatment, P 4 N was much more potent in causing cell death than NDGA in both cell lines.
The proinflammatory mediator LTB4 induces the expression of cytokines and chemokines; however, it can also be induced by proinflammatory cytokines and chemokines. We therefore used the LTA4H inhibitor bestatin to distinguish whether P 4 N induced the expression of the proinflammatory cytokines and chemokines through LTA4H activation or if it increased the activity of LTA4H through their induction. Fig. 6 C and D shows that P 4 N-induced expression of TNF-α and IL-8 was suppressed by bestatin. Thus, it appears P 4 N first activates LTA4H to increase LTB4 production and LTB4 then stimulates the expression of proinflammatory cytokines and chemokines.
Finally, it was discovered that bestatin inhibited the P 4 N-induced expression of activin A (Fig. 6E) , implicating P 4 N-activated LTA4H in the monocyte stimulation of the activin A/BAFF pathway. Macrophages act as mediators for stimulating activin A and releasing BAFF to induce B-cell activation. Depletion of macrophages by liposomal clodronate in CT26 tumor-bearing BALB/c mice (SI Appendix, Fig. S12 ) reduced the antitumor effects of P 4 N (Fig. 6F ) and clarified the direct target of P 4 N as the macrophage. The effect of bestatin on P 4 N-induced slowing of tumor growth was further examined, and the results showed bestatin abolished the P 4 N-induced inhibition of tumor growth (Fig. 6G ) and the expression of P 4 N-induced activin A and BAFF (Fig. 6H) .
Discussion
We report that low concentrations of the antitumor drug P 4 N contribute to the growth inhibition of colorectal tumors by enhancing the production of endogenous autoantibodies. P 4 N not only enhanced the proliferation of B cells to increase the titers of antibodies in sera (Fig. 3B) but also increased the activity of antitumor autoantibodies (SI Appendix, Fig. S13 ). The data presented in Fig.  3F revealed that although the titers of antitumor autoantibodies in PBS antisera and P 4 N antisera are different, they recognized the same antigens, GRP78 and F1F0 ATP synthase, in the membrane fraction ( Fig. 3G and SI Appendix, Fig. S3A ), indicating that the better antitumor efficacy of P 4 N antisera did not result from new antigen recognition but, instead, resulted from the improvement of the quantity and quality of the EAAs.
Without antigen stimulation, B cells cannot be activated and differentiate into plasma cells. Under these conditions, P 4 N causes B-cell proliferation and these proliferative B cells arrest at the naive B-cell stage (SI Appendix, Fig. S4 B and C) . With antigen stimulation and the help of CD4 + T cells, B cells that have been induced to proliferate by P 4 N will be further activated and differentiate into plasma cells (SI Appendix, Fig. S4F ). Thus, we have proposed that the promotion of EAA production by P 4 N treatment is the result of P 4 N-accelerated B-cell proliferation and differentiation (SI Appendix, Fig. S4 C and F) . This mechanism of action is consistent with the results of P 4 N suppression of CT26-derived tumors in mice ( Fig. 1 A and B) . In nude mice lacking CD4T cells, immature B cells are unable to mature and differentiate into antibody-producing plasma cells, rendering P 4 N ineffective. P 4 N retains some antitumor activity in BALB/c mice depleted of CD8T cells, because they still have CD4T cells to help B cells mature and produce antitumor antibodies. Further confirmation of this hypothesis will require additional experiments that examine whether the loss of efficacy seen in B-cell-depleted mice can be rescued by passive transfer of B cells from normal mice or BAFF-deficient mice. P 4 N-induced B-cell proliferation requires BAFF expression (Fig. 5) , which is induced by activin A through the ALK4/Smad3 signaling pathway. Similarly, Kim et al. (31) found that activin A can increase BAFF promoter activity and transcription via the ALK4/Smad3 pathway in mice APCs. The finding that P 4 Ninduced activin A is involved in the stimulation of B-cell proliferation is in accord with the report by Ogawa et al. (35) showing that lipopolysaccharide (LPS)-induced activin A can directly or indirectly increase B-cell proliferation and Ig production. Other reports have shown that activin A induces growth arrest and apoptosis in B-cell-derived cells and hybridomas (36, 37) . Activin A-induced apoptosis of B cells relies on the regulation of Bclfamily gene expression (38, 39) . Although activin A may cause B-cell apoptosis, BAFF can up-regulate the expression of Bcl-2a1 and down-regulate the expression of BIM for B-cell survival (40) . Our data indicate that P 4 N-induced B-cell proliferation is the result of BAFF directly stimulating the growth of B cells and preventing activin A-induced B-cell apoptosis. P 4 N improved the quality of the EAA response by inducing Ig class switching from IgM to IgG1 and IgA (Fig. 3C and SI Appendix, Fig. S4D) , and it enhanced their binding affinities (SI Appendix, Fig. S13 ). In the body, IgG1 and IgA easily diffuse into extravascular sites to access antigens and they have a greater efficacy for activating the complement system. Moreover, IgG1 also has a longer t 1/2 in the blood and can efficiently sensitize NK cells for killing. Thus, the P 4 N-induced class switch may be one of the reasons why the P 4 N antisera cause more efficient suppression of tumor growth than PBS antisera. Another reason may be that P 4 N enhances the process of somatic hypermutation in B cells that causes the antitumor autoantibodies in P 4 N antisera to have higher antigen-binding affinities than in PBS antisera, which results in the antitumor autoantibodies being able to bind on the tumor surface stably to trigger more efficient CDC or ADCC. The mechanism of the P 4 N-induced Ig class switch and somatic hypermutation involves the activin A-stimulated monocyte release of BAFF via the ALK4/Smad3 pathway (Fig. 5) . BAFF up-regulates the expression of the transcription factor Pax5/ BSAP, which sequentially increases the transcription of activationinduced cytidine deaminase (AID), an RNA editing enzyme responsible for IgH class switch recombination and somatic hypermutation (41) (42) (43) (44) . Moreover, class switch recombination must be supported by the splicing of germline transcripts (GLTs), which is involved in recruiting AID to S regions. Activin A also has been reported to induce the class switching of Ig to IgA and IgG2b in B cells through Smad2/3 signaling by up-regulating the expression of Ig germline transcript α (GLTα) and postswitch transcript α (PSTα) (45) . By these mechanisms, P 4 N could promote B-cell proliferation, differentiation, and function to produce higher titer and higher affinity autoantibodies against tumor growth. P 4 N directly interacted with and activated LTA4H to produce LTB4 (Fig. 6 ) and induce monocytes to release proinflammatory cytokines, chemokines, and activin A (Fig. 4A) . Subsequently, activin A stimulated monocytes in an autocrine manner to release BAFF via the ALK4/Smad3 pathway and activate B cells (Fig. 5) . According to the docking results, this unique function of P 4 N might be a result of its structure (Fig. 6A) . Unlike NDGA, which inhibits LTB4 production (33), the NDGA derivative P 4 N binds differently to LTA4H and acts as an activator and immune mediator to produce more LTB4 (Fig. 6B) . Once produced, LTB4 is transported out of the cells and binds to LTB4 receptors expressed primarily in leukocytes, and it mediates the monocytic up-regulation of TNF-α, IL-1β, and IL-6 (46) (47) (48) . As in the published literature, the inflammatory mediators, such as TNF-α, IL-1β, IFN-γ, and LPS, markedly enhance the production of activin A (49, 50) . Here, our results clearly indicate that an LTA4H activator can act on monocytes to stimulate the production of LTB4, resulting in B-cell proliferation and an increase of Ig production by serial production of autocrine signal mediators, such as TNF-α, activin A, and paracrine BAFF. A schematic representation of the proposed mechanism of action of P 4 N is presented in Fig. 7 .
GRP78 is an endoplasmic reticulum chaperone that facilitates protein assembly and regulates endoplasmic reticulum stress signaling. GRP78 resides not only in the endoplasmic reticulum but also in the nucleus and cytoplasm (51) . During the integrated stress response, the phosphorylation of eukaryotic initiation factor 2α (eIF2α) catalyzes translation initiation of GRP78 at the UUG and CUG start codons in its 5′-untranslated region upstream ORFs (52) . In malignant cells, GRP78 can translocate to the outside of the endoplasmic reticulum and to the cell surface (53, 54) . Increased levels of surface GRP78 in cancer cells are correlated with tumor progression, angiogenesis, and metastasis (53) (54) (55) . For CRC therapy, GRP78 silencing down-regulates the VEGF/VEGF receptor 2 pathway and suppresses human colon cancer tumor growth (55) . Furthermore, a natural IgM anti-GRP78 antibody, PAT-SM6, isolated from the sera of patients with cancer can specifically recognize the surface GRP78 and induce apoptosis to inhibit tumor growth (9, 10) . However, the natural GRP78 IgM has a low binding affinity and a restricted binding repertoire. To resolve this problem, a monoclonal anti-GRP78 antibody, mAb159, has been developed, and it can inhibit tumor growth and metastasis by modulating the PI3K pathway (56) .
The other antigen, F1F0 ATP synthase, generally localizes to the mitochondrial inner membrane and converts ADP to ATP in the process of mitochondrial oxidative phosphorylation. In cancer cells, cell surface-translocated F1F0 ATP synthases have been identified that promote tumor cell survival and develop an acidic microenvironment in tumor tissues through shear stress stimulation-induced ATP and H(+) corelease and CO 2 gas production (57) . Specific targeting of F1F0 ATP synthase by anti-ATP synthase β antibody led to the inhibition of cell proliferation (58) . In this study, we show the potential of an antitumor drug, P 4 N, converting inefficient EAAs against cell surface GRP78 and F1F0 ATP synthase into more efficient treatment modalities.
Patients with cancers other than CRC have been proven to generate autoantibodies in their sera that recognize their own tumor antigens (2) . However, these EAAs do not provide a therapeutic benefit for tumor elimination, and can even facilitate tumor growth. Passive transfer of antitumor antibodies offers a more efficient therapeutic modality. For example, a humanized monoclonal anti-GPR78 antibody (mAb159) that has shown inhibitory activity for CRC (56) has been developed. Patients with normal immunity who have cancer may negatively select out B cells with high activities against autoantigens, resulting in lowactivity EAAs. Although the process of somatic hypermutation can raise the activities of EAAs from low to high, the interaction of CD40 ligand of CD4 + T cells with CD40 on B cells to induce AID expression is necessary for this process. The autoreactive CD4 + T cells, however, will be depleted during T-cell development in the thymus by negative selection. In contrast, clinical target antibodies are artificially selected and produced, and their titers and activities can be raised by modern biotechniques, resulting in more efficient therapeutic effects. In vivo amelioration of EAAs is difficult, but we have shown that amelioration can be accomplished with low-dose P 4 N.
The breadth and potency of P 4 N's effect have not been fully addressed in this report. Our preliminary experiments show that i. v.-administered P 4 N is able to shrink the size of tumor explants of OVCAR-8 human ovarian cancer cells and inhibit the growth of LN229 human glioma cell-derived tumors in nude mice (SI Appendix, Fig. S14 ). The mechanism of P 4 N action in these cases, however, has not been determined. Whether the immune response elicited by P 4 N is potent enough of itself to eradicate tumors is not clear. To achieve complete remission and cures for patients with cancer, combining anticancer therapies has proven essential. For many tumors, the combination of immunotherapy and chemotherapy is the standard of care (59) . Immunomodulation with P 4 N may ultimately be most effective when used in combination with other chemotherapeutic agents.
Materials and Methods
Reagents. P 4 N was synthesized from NDGA by the Hwu laboratory, Department of Chemistry, National Tsing Hua University and provided for this study by R.C.C.H. SB431542 (ALK4 inhibitor), SIS-3 (Smad3 inhibitor), SB203580 (p38 inhibitor), and PD98059 (MAPK/ERK inhibitor) were purchased from Sigma-Aldrich. A83-01 (ALK4 inhibitor) was procured from R&D Systems. PBMCs were isolated from the blood of healthy human donors by density separation over Lymphoprep (Axis-Shield). Mononuclear cells at the interface were carefully transferred into a centrifuge tube and then treated with ACK hemolysis buffer (0.15 M NH 4 Cl, 10 mM KHCO 3 , 0.1 mM Na 2 EDTA), washed twice with PBS, and cultured in growth medium.
Total B cells were isolated from human PBMCs or mouse splenocytes by negative selection using a magnetic sorting device (Miltenyi Biotec). Briefly, PBMCs were incubated with a mixture of biotin-conjugated antibodies, followed by microbead-conjugated antibiotin antibodies for magnetic depletion. B cells were eluted according to the manufacturer's protocols. Human blood samples were collected from healthy individuals with their informed consent following an institutional review board (IRB)-approved protocol and in agreement with the Committee for Research Ethics Board of Chung Shan Medical University Hospital (IRB approved no. CS14047).
Animals. Female BALB/c and BALB/c/nude mice were purchased from The National Laboratory Animal Center and maintained on a 12:12-h light/dark cycle in an animal environmental control chamber (Micro-VENT IVC Systems). Humane animal care was ensured by use of the institutional guidelines of National Chiao Tung University (NCTU). The Committee on Animal Experimentation of the Center for Experimental Animals of the NCTU approved all studies and procedures. , the animals were treated with 2.5 mg/kg or 5 mg/kg of P 4 N in one intratumoral injection. Subsequently, the tumor volumes were measured using a caliper every 2 d, and the volumes were calculated using the following formula: volume (mm 3 ) = length × width × height. Before euthanasia, the sera of the mice were collected for experimental use.
In Vivo Cell Depletion. depletion of CD8T, B cells, and macrophages was evaluated by IHC staining. Tumor tissue was randomly selected from depleted animals; embedded in paraffin; and probed with rat monoclonal anti-CD20, anti-CD8, and anti-F4/80 antibodies (results are shown in SI Appendix, Figs. S12 and S15).
Sera Transfer in Vivo. In a metastatic model, BALB/c mice were i.v. injected with 1 × 10 6 CT26 cells in 100 μL of PBS via the tail vein, and then treated with 100 μL of antisera once every week. Upon the death of the mice, the lungs were dissected, observed, and photographed. Three mice in the P 4 N antisera group were killed 24 d after injection. Tumor nodules on the lungs were counted, and lung weights were determined. Survival of the mice was noted, and rates of survival were calculated. In an s.c. tumor model, the nude mice bearing ∼50-mm 3 CT26 tumors were injected i.v. with 100 μL of the different antisera once every week. The tumor volumes were measured as described above.
IHC Staining. Tumors isolated from P 4 N-and vehicle-treated mice were embedded in paraffin, and thin sections were made and processed for IHC staining. The sections were probed with rat monoclonal anti-F4/80 (1:50 dilution; GeneTex) and anti-CD20 (1:200 dilution; Santa Cruz Biotechnology), hamster monoclonal anti-CD11c (1:25 dilution; GeneTex), rabbit monoclonal anti-CD3 (1:50 dilution; GeneTex), and rabbit polyclonal anti-TNF-α and anti-IL-8 antibodies (1:50 dilution; Assay BioTech) at 4°C overnight, and the detection antibodies were recognized using a horseradish peroxidase (HRP)-conjugated anti-rat, anti-hamster, or anti-rabbit IgG antibody (1:1,500 dilution; Santa Cruz Biotechnology). The immune complexes in the sections were visualized using the LSAB2 System (DAKO). The sections were counterstained with hematoxylin, mounted, observed under a light microscope at a magnification of 400×, and photographed.
Sections of CT26 tumors from untreated mice were incubated with a 200-fold dilution of normal sera, PBS antisera, or P 4 N antisera at 4°C overnight. The sections were then incubated with an HRP-conjugated anti-mouse IgG antibody (1:1,500 dilution; Santa Cruz Biotechnology), developed, counterstained, and photographed as described above.
Titers and Ig Classes of Antitumor Autoantibodies. Blood was collected weekly from CT26-bearing mice treated with PBS or 5 mg/kg P 4 N, and the titers of CT26-specific antibodies in the sera were measured by the following method. The wells of 96-well culture plates were seeded with CT26 (10 6 cells per well) or mouse mammary gland adenocarcinoma JC cells (10 6 cells per well). On the following day, the cells were fixed with 4% (wt/vol) paraformaldehyde, washed, and blocked with 300 μL of 2% (wt/vol) skim milk in PBST (PBS buffer with 0.05% Tween-20) for 1 h. One hundred microliters of 6,400-fold diluted sera in PBS containing 0.5% skim milk was loaded into each well and incubated at room temperature for 2 h. After washing three times, 100 μL of HRP-conjugated anti-mouse Ig antibody (1:10,000 dilution; Sigma-Aldrich) was added to each well and incubated for 1 h. After washing three times, 100 μL of NeA-Blue (Clinical Science Products, Inc.) was added to each well, incubated for 20 min, and stopped using 100 μL of 1-N HCl. The optical density was measured at 450 nm using an ELISA reader (Tecan). The isotypes of specific anti-CT26 cell antibodies in antisera (1:1,600 dilution) were determined by using HRP-conjugated specific anti-mouse IgM, IgG1, IgG2a, IgG2b, or IgA antibodies (Acris).
Immunofluorescence Analysis of Cell Surface Tumor Antigens. CT26 cells were seeded on glass cover slides, and fixed with 4% (wt/wt) paraformaldehyde The fixed cells were then incubated with normal sera, PBS antisera, or P 4 N antisera for 1 h and detected with secondary antibodies conjugated to Alexa Fluor 568 (Molecular Probes). Alexa Fluor 488-conjugated Con A (Molecular Probes) and DAPI (Molecular Probes) were used to label the plasma membrane and nucleus, respectively. The images of tumor antigens recognized by the antisera were photographed at a magnification of 400× using a Zeiss LSM 510 META confocal microscope (Carl Zeiss).
Western Blot Analysis. The membrane proteins of 3 × 10 7 CT26 cells were extracted and harvested with the Mem-PER Eukaryotic Membrane Protein Extraction Reagent Kit (Thermo Fisher Scientific), following the manufacturer's instructions. Fifty micrograms of total membrane protein was subjected to SDS/PAGE; transferred to Nitrocellulose Blotting Membrane (General Electric); and probed with normal sera, PBS antisera, or P 4 N antisera. The membranes were then blocked with 2% (wt/vol) milk in PBST, incubated with HRP-conjugated anti-mouse Ig antibody (1:10,000 dilution; Sigma-Aldrich), and developed with the WesternBright ECL Western blotting detection kit (Advansta). Antibody-bound proteins were visualized by the Hansor Luminescence Image System (Hansor). E-cadherin proteins in all samples were probed by rabbit polyclonal anti-E-cadherin antibody (1:1,000 dilution; GeneTex) and HRP-conjugated anti-rabbit Ig antibody (1:10,000 dilution; Sigma-Aldrich).
Co-Immunoprecipitation Assay. Five microliters of normal sera, PBS antisera, or P 4 N antisera was mixed with 100 μL of protein G agarose (Merck Millipore), and then covalently linked with disuccinimidyl suberate (Thermo Fisher Scientific). After washing, 5 μL of protein G agarose-conjugated sera was incubated with 400 μL of membrane proteins at room temperature. The immune complexes were then washed three times with lysis buffer and eluted with elution buffer (Thermo Fisher Scientific). The precipitated samples were then heated in reducing sample buffer and resolved by the SDS/PAGE.
Antigen Identification by UPLC/HRMS/MS. Proteins were excised from SDS polyacrylamide gels, digested with the In-Gel Tryptic Digestion Kit (Thermo Fisher Scientific), and identified by UPLC/HRMS/MS (Bruker BioSpin). Peptide sequence information was used to search sequences in the protein database of the National Center for Biotechnology Information using BLAST (blast.ncbi.nlm.nih.gov/blast.cgi).
Cytokine Multiplex Assay. THP-1 cells (5 × 10 5 cells per milliliter) in 1 mL of culture medium were seeded in each well of a 24-well microplate and treated with 3 μM P 4 N for 24 h. Cell culture supernatants were collected and analyzed by a cytokine multiplex assay following the Bio-Plex Pro Human Cytokine Standard Group I 27-Plex, according to the manufacturer's protocol (Bio-Rad). The change levels of cytokine were calculated as follows: Change level = (value of the P 4 N-treated cells)/(value of the untreated cells) × 100%.
Gene Expression Profiling and Analysis. Amplification and labeling of RNA were performed with the IlluminaTotalPrep RNA Amplification Kit from Life Technologies (Ambion; Applied Biosystems) using 150 ng of RNA per sample. Labeled RNA (750 ng) was hybridized to Illumina HT-12 v4 Expression BeadChips (∼48,000 probes) and processed according to the manufacturer's protocol.
Expression data underwent quality control and normalization by Genome Studio (Illumina). Genes differentially expressed in the cells treated with P 4 N relative to the untreated cells were identified, with special emphasis given to genes involved in cytokine-cytokine receptor interaction (KEGG pathway). Genes with a P value <0.05 and a fold change ≥0.4 were considered to be differentially expressed, up-regulated genes. The identified genes were subjected to the Database for Annotation, Visualization, and Integrated Discovery (https://david.ncifcrf.gov/) for GO and KEGG pathway enrichment analysis. A P value <0.05 was set as the threshold of enrichment analysis.
RT-PCR.
Human PBMCs or THP-1 cells were treated with P 4 N, and the mRNA expression of activin A and BAFF in these cells was then measured by RT-PCR. Briefly, total cellular RNA was extracted with TRIzol reagent (Invitrogen) and reverse-transcribed into cDNA using the SuperScript RT-Kit (Invitrogen). The cDNA of activin A and BAFF was then amplified by PCR. The primers for human activin A were forward primer 5′-GCCGAGTCAGGAACAGCCAG-3′ and reverse primer 5′-TTTCTTCTTCTTCTTGCCCAGGA-3′, and the primers for human BAFF were forward primer 5′-ATGGATGACTCCACAGAAAGG-3′ and reverse primer 5′-TGGTAGAAAGACACCACCG-3′. All PCR reagents used to amplify the cDNA were purchased from Promega. GAPDH cDNA in the samples was used to normalize the loading amounts in each reaction. Finally, PCR products were resolved by electrophoresis on 2% agarose gels, stained with ethidium bromide, and photographed using the Uni-photo band tool (EZ laboratory). ELISAs. THP-1 cells (1 × 10 6 cells per milliliter per well) in a 24-well culture plate were pretreated with 10 μM bestatin (LTA4H inhibitor; Sigma-Aldrich) for 2 h and then treated with 3 μM P 4 N for various time intervals. The levels of LTB4 in the culture media were determined by the LTB4 ELISA Kit (Enzo Life Sciences). The amounts of TNF-α, IL-8, and activin A in the cultured media were measured in a similar manner.
Cell Proliferation
Statistical Analyses. The results are presented as the mean ± SEM. The statistical significance was evaluated using Student's t test, and P < 0.05 was considered significant.
